Filing Worth Mentioning: Protokinetix, Inc: Smith Clarence Edward Opened Big New Position

Filing Worth Mentioning: Protokinetix, Inc: Smith Clarence Edward Opened Big New Position

The New Smith Clarence Edward Holding in Protokinetix, Inc

Smith Clarence Edward filed with the SEC SC 13D/A form for Protokinetix, Inc. The form can be accessed here: 000107997316001254. As reported in Smith Clarence Edward’s form, the filler as of late owns 23.75% or 55,214,726 shares of the -company.

Protokinetix, Inc stake is a new one for the and it was filed because of activity on November 4, 2016. We feel this shows Smith Clarence Edward’s positive view for the stock.

Business Profile

ProtoKinetix, Incorporated is a research and development-stage bio-technology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins, known as AAGPs. AFGP is found in nature as a compound produced by some fish, insects, reptiles, bacteria and plants that enable survival in freezing temperatures. Health Care Applications of AAGP fall into various categories, such as harvesting, storage and transplanting cells, tissues and organs, and treatments for conditions and diseases caused by stress factors, including ultraviolet (UV) radiation, oxidation and inflammation. The Company is engaged in preparing to start Phase I and Phase II human clinical trials at the University of Alberta.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

The stock increased 9.77% or $0.006 on November 7, hitting $0.0674. About 131,700 shares traded hands or 50.41% up from the average. ProtoKinetix, Inc. (OTCMKTS:PKTX) has risen 70.63% since April 11, 2016 and is uptrending. It has outperformed by 68.68% the S&P500.

ProtoKinetix, Incorporated is a research and development-stage bio-technology company. The company has a market cap of $16.48 million. The Firm is focused on scientific medical research of Anti-Freeze Glycoproteins or anti-aging glycoproteins, known as AAGPs. It currently has negative earnings. AFGP is found in nature as a compound produced by some fish, insects, reptiles, bacteria and plants that enable survival in freezing temperatures.

More notable recent ProtoKinetix, Inc. (OTCMKTS:PKTX) news were published by: Streetinsider.com which released: “Form 4 ProtoKinetix, Inc. For: Nov 04 Filed by: SMITH CLARENCE EDWARD” on November 08, 2016, also Businesswire.com with their article: “ProtoKinetix Reports on Its Strong Collaboration with the James Shapiro …” published on August 04, 2015, Businesswire.com published: “ProtoKinetix Announces Appointment of New Director and Provides Corporate Update” on July 01, 2015. More interesting news about ProtoKinetix, Inc. (OTCMKTS:PKTX) were released by: Businesswire.com and their article: “ProtoKinetix Corporate Update” published on January 05, 2016 as well as Businesswire.com‘s news article titled: “AAGPâ„¢ Found to Significantly Improve Islet Cell Transplantation in Type 1 …” with publication date: December 17, 2015.

PKTX Company Profile

ProtoKinetix, Incorporated, incorporated on December 23, 1999, is a research and development-stage bio-technology company. The Firm is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins, known as AAGPs. AFGP is found in nature as a compound produced by some fish, insects, reptiles, bacteria and plants that enable survival in freezing temperatures.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment